CopyMark Law Group
4.9/5
Drawing for JIXING

USPTO serial 97407895

JIXING

Reviewed by CopyMark Law Group

Reg. 7593041Status 700Registered
Filing date
Status date
Registration date
Dec 10, 2024
Examiner
ABRAMS, JACQUELINE WILLETTE
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with JIXING?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Erica Halstead

Erica Halstead WOMBLE BOND DICKINSON (US) LLP950 THIRD AVENUE24TH FLOORNEW YORK, NY 10022

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of asthma; cholesterol reducers; antihypertensives; anti-diabetic pharmaceuticals; anti-diabetic preparations; antiarrhythmics; cardiovascular pharmaceutical preparations; pharmaceutical preparation for eye or intraocular surgery; ophthalmic pharmaceutical products; ophthalmic preparations; medical preparations for use with eyes; medicines for the treatment of cardiovascular diseases; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; depuratives for the body; medicines for veterinary purposes, namely, veterinary diagnostic reagents, veterinary vaccines, Anti-infective products for veterinary use, and Veterinary preparations, namely, pain relief medication; Enzymes for veterinary purposes; biocides; disinfectant wipes; preparations to facilitate teething; diapers for pets; pharmaceutical candy, namely, medicated candies; medicines for human purposes, namely, human vaccine preparations, Antibiotics for human use, anti-allergic and pain reduction medicines for treatment of illnesses for human purposes; pharmaceutical preparations, namely, pharmaceutical preparations for treatment of human illnesses, namely, heart disease and cancer; chemico-pharmaceutical preparations, namely, chemico-pharmaceutical preparations for treatment of human illnesses, namely, heart disease and cancer; ointments for pharmaceutical purposes, namely, antibiotic, sunburn, anti-inflammatory ointments for pharmaceutical purposes; bronchodilating preparations; injectable pharmaceuticals, namely, injectable pharmaceuticals for treatment of anaphylactic reactions; tablets for pharmaceutical purposes, namely, medicinal preparations for the mouth to be applied in the form of tablets and compressed tablets; tincture of iodine; herbal tinctures for medical purposes; pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hypercholesterolemiaACTIVE—
042Scientific research and development; development of pharmaceutical preparations and medicines; biomedical research services; medical research services; chemical research; biotechnology research; drug testing services; Software as a service (SAAS) services featuring software for analyzing and reporting self-assessment of illness; Software as a service (SAAS) services, namely, hosting software for use by others for use in database management, use as a spreadsheet, word processing; pharmaceutical drug research services; pharmaceutical drug development servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 10, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Dec 10, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 10, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 10, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 21, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 6, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 4, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 4, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 2, 2024ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Jan 22, 2024GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jan 22, 2024GNSLLETTER OF SUSPENSION E-MAILED—
Jan 22, 2024CNSLSUSPENSION LETTER WRITTEN—
Jan 22, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 22, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 22, 2024ALIEASSIGNED TO LIE—
Aug 30, 2023ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Jun 8, 2023GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Jun 8, 2023GNSIINQUIRY TO SUSPENSION E-MAILED—
Jun 8, 2023CNSISUSPENSION INQUIRY WRITTEN—
Nov 30, 2022GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Nov 30, 2022GNSLLETTER OF SUSPENSION E-MAILED—
Nov 30, 2022CNSLSUSPENSION LETTER WRITTEN—
Nov 29, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 29, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 29, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 31, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 31, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 31, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 30, 2022DOCKASSIGNED TO EXAMINER—
May 18, 2022MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
May 17, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 16, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance